A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials

Summary

The main objectives of this study are to evaluate the long-term safety of spesolimab in patients with perianal fistulising Crohn's disease who have completed treatment in parent trials and to evaluate the long-term efficacy of spesolimab in patients with perianal fistulising Crohn's disease, who have completed treatment in parent trials

Timeline

Start

2020-05-15

Primary completion

2022-05-14

Completion

2022-09-23

Outcome

Outcome not reported

Stopped: “BI's decision to terminate the development of spesolimab in fistulising and fibrostenotic Crohn's disease.”

Drugs

Indications